Literature DB >> 21371489

Progesterone signaling mediated through progesterone receptor membrane component-1 in ovarian cells with special emphasis on ovarian cancer.

John J Peluso1.   

Abstract

Various ovarian cell types including granulosa cells and ovarian surface epithelial cells express the progesterone (P4) binding protein, progesterone receptor membrane component-1 (PGRMC1). PGRMC1 is also expressed in ovarian tumors. PGRMC1 plays an essential role in promoting the survival of both normal and cancerous ovarian cell in vitro. Given the clinical significance of factors that regulate the viability of ovarian cancer, this review will focus on the role of PGRMC1 in ovarian cancer, while drawing insights into the mechanism of PGRMC1's action from cell lines derived from healthy ovaries as well as ovarian tumors. Studies using PGRMC1siRNA demonstrated that P4's ability to inhibit ovarian cells from undergoing apoptosis in vitro is dependent on PGRMC1. To confirm the importance of PGRMC1, the ability of PGRMC1-deplete ovarian cancer cell lines to form tumors in intact nude mice was assessed. Compared to PGRMC1-expressing ovarian cancer cells, PGRMC1-deplete ovarian cancer cells formed tumors in fewer mice (80% compared to 100% for controls). Moreover, the number of tumors derived from PGRMC1-deplete ovarian cancer cells was 50% of that observed in controls. Finally, the tumors that formed from PGRMC1-deplete ovarian cancer cells were about a fourth the size of tumors derived from ovarian cancer cells with normal levels of PGRMC1. One reason for PGRMC1-deplete tumors being smaller is that they had a poorly developed microvasculature system. How PGRMC1 regulates cell viability and in turn tumor growth is not known but part of the mechanism likely involves the regulation of genes that promote cell survival and inhibit apoptosis.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21371489      PMCID: PMC3129485          DOI: 10.1016/j.steroids.2011.02.011

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  31 in total

Review 1.  Angiogenesis as a strategic target for ovarian cancer therapy.

Authors:  Whitney A Spannuth; Anil K Sood; Robert L Coleman
Journal:  Nat Clin Pract Oncol       Date:  2008-02-12

2.  Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells.

Authors:  Udit N Verma; Rama M Surabhi; Aurelia Schmaltieg; Carlos Becerra; Richard B Gaynor
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

3.  Peritoneal fluid gonadotropins and ovarian hormones in patients with ovarian cancer.

Authors:  R. Halperin; E. Hadas; R. Langer; I. Bukovsky; D. Schneider
Journal:  Int J Gynecol Cancer       Date:  1999-11       Impact factor: 3.437

4.  Retinoic acid determines life span of leukemic cells by inducing antagonistic apoptosis-regulatory programs.

Authors:  Weihong Yin; Wolfgang Raffelsberger; Hinrich Gronemeyer
Journal:  Int J Biochem Cell Biol       Date:  2005-04-25       Impact factor: 5.085

5.  Expression and function of a proapoptotic Bcl-2 family member Bcl-XL/Bcl-2-associated death promoter (BAD) in rat ovary.

Authors:  A Kaipia; S Y Hsu; A J Hsueh
Journal:  Endocrinology       Date:  1997-12       Impact factor: 4.736

6.  The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.

Authors:  Hilary A Kenny; Swayamjot Kaur; Lisa M Coussens; Ernst Lengyel
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

7.  Induction of senescence by progesterone receptor-B activation in response to cAMP in ovarian cancer cells.

Authors:  Akira Takahashi; Kiyoko Kato; Ayumi Kuboyama; Takafumi Inoue; Yoshihiro Tanaka; Aya Kuhara; Katsuyuki Kinoshita; Satoru Takeda; Norio Wake
Journal:  Gynecol Oncol       Date:  2009-02-10       Impact factor: 5.482

Review 8.  Non-genomic actions of progesterone in the normal and neoplastic mammalian ovary.

Authors:  John J Peluso
Journal:  Semin Reprod Med       Date:  2007-05       Impact factor: 1.303

9.  Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1.

Authors:  John J Peluso; Xiufang Liu; M Melinda Saunders; Kevin P Claffey; Kathryn Phoenix
Journal:  J Clin Endocrinol Metab       Date:  2008-03-04       Impact factor: 5.958

10.  Effects of progesterone and anti-progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3.

Authors:  Raffaèle Fauvet; Charlotte Dufournet Etienne; Christophe Poncelet; Annie-France Bringuier; Gérard Feldmann; Emile Daraï
Journal:  Oncol Rep       Date:  2006-04       Impact factor: 3.906

View more
  29 in total

1.  Alterations in progesterone receptor membrane component 2 (PGRMC2) in the endometrium of macaques afflicted with advanced endometriosis.

Authors:  Christopher S Keator; Kuni Mah; Ov D Slayden
Journal:  Mol Hum Reprod       Date:  2012-02-03       Impact factor: 4.025

2.  Progesterone increases the release of brain-derived neurotrophic factor from glia via progesterone receptor membrane component 1 (Pgrmc1)-dependent ERK5 signaling.

Authors:  Chang Su; Rebecca L Cunningham; Nataliya Rybalchenko; Meharvan Singh
Journal:  Endocrinology       Date:  2012-07-09       Impact factor: 4.736

3.  Progesterone receptor membrane component 1 deficiency attenuates growth while promoting chemosensitivity of human endometrial xenograft tumors.

Authors:  Anne M Friel; Ling Zhang; Cindy A Pru; Nicole C Clark; Melissa L McCallum; Leen J Blok; Toshi Shioda; John J Peluso; Bo R Rueda; James K Pru
Journal:  Cancer Lett       Date:  2014-10-07       Impact factor: 8.679

4.  Progesterone directly and rapidly inhibits GnRH neuronal activity via progesterone receptor membrane component 1.

Authors:  Nicholas Michael Bashour; Susan Wray
Journal:  Endocrinology       Date:  2012-07-20       Impact factor: 4.736

5.  Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors.

Authors:  Nicole C Clark; Anne M Friel; Cindy A Pru; Ling Zhang; Toshi Shioda; Bo R Rueda; John J Peluso; James K Pru
Journal:  Cancer Biol Ther       Date:  2016-01-19       Impact factor: 4.742

6.  Conditional Ablation of Progesterone Receptor Membrane Component 1 Results in Subfertility in the Female and Development of Endometrial Cysts.

Authors:  Melissa L McCallum; Cindy A Pru; Yuichi Niikura; Siu-Pok Yee; John P Lydon; John J Peluso; James K Pru
Journal:  Endocrinology       Date:  2016-06-16       Impact factor: 4.736

7.  Plasminogen activator inhibitor 1 RNA-binding protein interacts with progesterone receptor membrane component 1 to regulate progesterone's ability to maintain the viability of spontaneously immortalized granulosa cells and rat granulosa cells.

Authors:  John J Peluso; Angela Yuan; Xiufang Liu; Valentina Lodde
Journal:  Biol Reprod       Date:  2013-01-25       Impact factor: 4.285

Review 8.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

9.  Enhancement of cell surface expression and receptor functions of membrane progestin receptor α (mPRα) by progesterone receptor membrane component 1 (PGRMC1): evidence for a role of PGRMC1 as an adaptor protein for steroid receptors.

Authors:  Peter Thomas; Yefei Pang; Jing Dong
Journal:  Endocrinology       Date:  2014-01-01       Impact factor: 4.736

10.  The PGRMC1 Protein Level Correlates with the Binding Activity of a Sigma-2 Fluorescent Probe (SW120) in Rat Brain Cells.

Authors:  Chenbo Zeng; Neha Garg; Robert H Mach
Journal:  Mol Imaging Biol       Date:  2016-04       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.